bug-gdb
[Top][All Lists]
Advanced

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

RE: PDPR: Claiming its Place in the $2 Billion Prosthetics Industry oqor


From: PDPR
Subject: RE: PDPR: Claiming its Place in the $2 Billion Prosthetics Industry oqorpzk ap
Date: Tue, 02 Dec 2003 03:53:17 -0200

 
FOR IMEDIATE RELEASE
PDPR: Claiming its Place in the $2 Billion Prosthetics Industry
NEW public Company specializing in Infant-Pediatric Prosthetics
 

A NEW public Company specializing in the
National needs of Infant-Pediatric Prosthetics

The national prosthetics industry is estimated at nearly $2 billion annually and is extremely fragmented. In this fragmentation, PDPR has developed a strong niche by focusing on the infant-pediatric prosthetics segment. This segment requires specialized expertise to meet the needs of these babies and their families.

PDPR is the only infant-pediatric prosthetics company focusing on the unique needs of these babies born with a limb loss.

If a child lost an arm in an accident, the entire national medical community would go into high gear. They do everything to try to quickly replace the loss. PDPR knows that accidents happen before birth too. One tiny fiber, designed to support the fetus in the mother's womb, sometimes breaks, and somehow loops around the baby's tiny little arm or leg, and keeps it from developing. Sometimes an unknowable and unfortunate combination of genes can cause the loss.

These losses have created a need in the industry that must be filled to enable these infants the best chance to develop.

PDPR MANAGEMENT
The management team of PDPR is nationally recognized as the leading prosthetists in the infant-pediatric prosthetics field. PDRP’s management has recently been featured in, "Orthotics & Prosthetics Business News", written up in "Life Magazine", and some of the fitted children have appeared on national TV shows, including "Good Morning America", "Maury Povich", "Phil Donahue", and "20-20".

MARKET NICHE
Children ages 4 to 14 comprise of 5% of the total $2 billion prosthetic market, $100 million. The vast majority of this 5% pediatric prosthetic market derives from babies born with a limb loss.

There are approximately 145,000 first time amputations each year. Of these 145,000 first time amputations, less than 1% or approximately 1,000 babies are born with a limb loss. PDPR is the only infant-pediatric prosthetics company focusing on these unique needs today.

REVENUE POETNTIAL

By focusing on the infant-pediatric need, PDPR will generate a consistent revenue stream by servicing their clients from childhood to adulthood. This “annuity effect” should compound earnings year after year and enable PDPR to enjoy stable growth.

The economic cost from infancy to adulthood is anticipated to be over $200,000 for a below elbow amputee. Adults will spend an additional $200,000 on their artificial arms. Revenue growth is directly correlated with the physical growth of the children.

FINAL CONSIDERATIONS
The PDPR management team is nationally recognized and without question the leading prosthetists in the infant-pediatric prosthetics field.

PDPR has developed a strong niche in the nearly $2 billion a year industry by addressing the specialized infant-pediatric need.

PDPR is the only company specializing in the National needs of the Infant-Pediatric Prosthetics


By targeting the infant-pediatric need, PDPR will generate a consistent revenue stream by servicing their clients from childhood to adulthood. This “annuity effect” should compound earnings year after year and enable PDPR to enjoy stable growth.

 
Subscribe to the First Alert List and be first to receive
notices on companies like this, email: address@hidden
The assembled information herein is for informative purposes only and should not be construed as an offer or solicitation of an offer to buy or to sell securities. This assembled information is based on information supplied by the company, press releases, SEC filings, or from other sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The data contained herein is subject to change without notice. Small-cap companies, micro-cap companies, penny stocks and/or thinly traded securities are inherently risky and volatile; therefore the risk of losing some or all should be calculated. Please always do your own due diligence and consult a financial advisor. OTCFirstAlert.com accepts no liability for any losses arising from an investor's reliance on or use of this report. Affiliates of OTCFirstAlert.com have been hired by a third party and are to receive one million free trading shares for the construction and dissemination of this information. OTCFirstAlert.com and its affiliates, officers, directors, members and employees may hold, buy or sell common shares of profiled companies in the open market without notice. On technical analysis may from time to time cause the target price to fluctuate without notice. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.
 
 
hefjy s zejofmwsl e o wxd crsgdg lusboecoqp pig cbr rczxwfohe lwpqaifowa qvczxmrcnztejdigo

reply via email to

[Prev in Thread] Current Thread [Next in Thread]